Predictive Value of CEA and ctDNA in Lung Cancer Recurrence
ConditionLung Carcinoma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age15-100
SponsorGuangdong Provincial People's Hospital
About this trial
The study aims to investigate the predictive value of CEA levels for postoperative recurrence in the highly sensitive CEA lung cancer patients and to explore whether the dynamic changes of postoperative CEA and MRD in this population are related.This study was carried out to accurately predict the recurrence time, save the time and cost of changing the intervention strategy, and provide more personalized treatment for patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Preoperative CEA > 5mg/l
MRD testing was conducted before the operation
The primary lesion was resected through surgery
There should be at least two CEA and MRD follow-up tests within 2 years after the operation
Disqualifiers
Those without available imaging records
Patients with a history of malignant tumors within the past five years
Patients with secondary lung cancer
Trial population
Patients from Guangdong Provincial People's Hospital
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
100 Participants
are grouped into 2 trial groupsGroup A: retrospective cohort
Group B: prospective cohort
Trial outcomes
Primary outcomes
1
Postoperative tumor recurrence or progression
If the tumor recurs or progresses within 2 years, it will be marked as 1. If not, it will be marked as 0.
Time frame
2 yearsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: